TG8-260

TG8-260 is a potent and orally bioavailable EP2 receptor antagonist developed for research on neuroinflammatory and peripheral inflammatory diseases. It demonstrates efficacy in reducing gliosis and inflammation in rodent seizure models and inhibits pro-inflammatory gene expression in microglial cell assays, supporting its use in both in vivo and in vitro anti-inflammatory pathway studies.